| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
15,880,000 |
| Market
Cap: |
93.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.46 - $7.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ClearPoint Neuro is a commercial-stage medical device company that develops and commercializes platforms for performing minimally invasive surgical procedures in the brain. Co.'s ClearPoint system is designed to allow minimally invasive procedures in the brain to be performed in a hospital's existing Magnetic Resonance Imaging (MRI) suite or in an inter-operative MRI. Co.'s ClearPoint Array Neuro Navigation System can be used in an MRI suite or in an operating room setting. Co.'s ClearPoint system is an integrated system comprised of hardware components, disposable components and intuitive, menu-driven software.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
18,867 |
| Total Sell Value |
$0 |
$0 |
$0 |
$303,193 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dalessandro Danilo |
Chief Financial Officer |
• – – |
2023-08-20 |
4 |
D |
$5.34 |
$6,226 |
D/D |
(1,166) |
52,408 |
|
- |
|
| Burnett Joseph Michael |
CEO and President |
• • – |
2023-07-09 |
4 |
D |
$6.58 |
$40,283 |
D/D |
(6,122) |
249,659 |
|
- |
|
| Stigall L. Jeremy |
GM, Biologics & Drug Delivery |
• – – |
2023-07-06 |
4 |
D |
$6.53 |
$11,297 |
D/D |
(1,730) |
42,646 |
|
- |
|
| Girin Pascal E R |
Director |
– • – |
2023-07-03 |
4 |
A |
$7.24 |
$7,182 |
D/D |
992 |
51,496 |
|
- |
|
| Fletcher R John |
Director |
– • – |
2023-07-03 |
4 |
A |
$7.24 |
$5,778 |
D/D |
798 |
71,943 |
|
- |
|
| Richards Timothy T. |
Director |
– • – |
2023-07-03 |
4 |
A |
$7.24 |
$11,150 |
D/D |
1,540 |
38,899 |
|
- |
|
| Dalessandro Danilo |
Chief Financial Officer |
• – – |
2023-06-30 |
4 |
A |
$6.15 |
$8,432 |
D/D |
1,371 |
53,574 |
|
- |
|
| Burnett Joseph Michael |
CEO and President |
• • – |
2023-06-30 |
4 |
A |
$6.15 |
$12,884 |
D/D |
2,095 |
255,781 |
|
- |
|
| Stigall L. Jeremy |
GM, Biologics & Drug Delivery |
• – – |
2023-06-30 |
4 |
A |
$6.15 |
$16,494 |
D/D |
2,682 |
44,376 |
|
- |
|
| Sabra Mazin |
Chief Operating Officer |
• – – |
2023-06-30 |
4 |
A |
$6.15 |
$3,395 |
D/D |
552 |
47,452 |
|
- |
|
| Burnett Joseph Michael |
CEO and President |
• • – |
2023-06-10 |
4 |
D |
$6.91 |
$48,038 |
D/D |
(6,952) |
253,686 |
|
- |
|
| Stigall L. Jeremy |
GM, Biologics & Drug Delivery |
• – – |
2023-06-10 |
4 |
D |
$6.91 |
$8,375 |
D/D |
(1,212) |
41,694 |
|
- |
|
| Dalessandro Danilo |
Chief Financial Officer |
• – – |
2023-06-10 |
4 |
D |
$6.91 |
$17,455 |
D/D |
(2,526) |
52,203 |
|
- |
|
| Stigall L. Jeremy |
GM, Biologics & Drug Delivery |
• – – |
2023-02-22 |
4 |
D |
$8.55 |
$4,395 |
D/D |
(514) |
42,906 |
|
- |
|
| Richards Timothy T. |
Director |
– • – |
2023-01-03 |
4 |
A |
$7.97 |
$11,150 |
D/D |
1,399 |
36,038 |
|
- |
|
| Fletcher R John |
Director |
– • – |
2023-01-03 |
4 |
A |
$7.97 |
$17,335 |
D/D |
2,175 |
70,461 |
|
- |
|
| Johnson B Kristine |
Director |
– • – |
2023-01-03 |
4 |
A |
$7.97 |
$3,435 |
D/D |
431 |
20,453 |
|
- |
|
| Girin Pascal E R |
Director |
– • – |
2023-01-03 |
4 |
A |
$7.97 |
$7,181 |
D/D |
901 |
49,653 |
|
- |
|
| Sabra Mazin |
Chief Operating OfficerOfficer |
• – – |
2022-10-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
900 |
|
-12% |
|
| Sabra Mazin |
Chief Operating Officer |
• – – |
2022-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
46,000 |
46,900 |
|
- |
|
| Johnson B Kristine |
Director |
– • – |
2022-10-03 |
4 |
A |
$10.19 |
$3,434 |
D/D |
337 |
20,022 |
|
- |
|
| Girin Pascal E R |
Director |
– • – |
2022-10-03 |
4 |
A |
$10.19 |
$7,184 |
D/D |
705 |
48,752 |
|
- |
|
| Fletcher R John |
Director |
– • – |
2022-10-03 |
4 |
A |
$10.19 |
$17,343 |
D/D |
1,702 |
68,286 |
|
- |
|
| Richards Timothy T. |
Director |
– • – |
2022-10-03 |
4 |
A |
$10.19 |
$11,148 |
D/D |
1,094 |
34,639 |
|
- |
|
| Dalessandro Danilo |
Chief Financial Officer |
• – – |
2022-09-29 |
4 |
D |
$10.23 |
$50,720 |
D/D |
(4,958) |
53,477 |
|
- |
|
311 Records found
|
|
Page 2 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.34 (5.48%) 
